The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Improving TTD and supporting patient advocacy in CTCL
Chalid Assaf
• 14 Oct 2021
Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, highlights key areas of research in the field of cutaneous T-cell lymphoma (CTCL), in particular focusing on the need to reduce the time to diagnosis (TTD) and the importance of patient advocacy. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
